-
February 15, 2013
Weight Watchers offers more excuses and poor performance.
-
February 07, 2013
Vivus Inc. (VVUS) recently announced the publication of results from a study regarding its weight-loss drug, Qsymia. ...
-
January 23, 2013
Arena Pharmaceuticals Inc. (ARNA) recently received 'The Day 180 List of Outstanding Issues' from the European ...
-
January 10, 2013
Orexigen Therapeutics, Inc. (OREX) recently provided an update on its obesity candidate, Contrave. The company, ...
-
December 31, 2012
Takeda Pharmaceutical Company Limited (TKPYY) recently announced that it has mutually terminated its worldwide ...
-
December 28, 2012
Biotech stocks have been major outpeformers in 2012.
-
November 09, 2012
Arena Pharmaceuticals Inc.'s (ARNA) loss (excluding special items) of 7 cents per share in the third quarter of 2012 ...
-
November 08, 2012
Vivus Inc. (VVUS) reported a loss of 40 cents per share in the third quarter of 2012, wider than the Zacks Consensus ...
-
November 06, 2012
Weight Watchers continues to struggle to exploit its huge market opportunity.
-
October 22, 2012
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently did not ...
-
October 15, 2012
Arena Pharmaceuticals, Inc. (ARNA) recently initiated a phase I multiple dose study with APD811, which is being ...
-
September 25, 2012
Vivus Inc. (VVUS) recently announced that it expects the European Medicines Agency's (EMA) Committee for Medicinal ...
-
September 20, 2012
Vivus Inc. (VVUS) recently announced the launch of its obesity drug, Qsymia, in the US following the US Food and ...
-
September 06, 2012
The morning has been good for the market. The Nasdaq has risen 1.9%; the S&P 500 is up 1.8%; and the Dow has moved ...
-
September 05, 2012
Among the biggest winners in Wednesday's early trading are Guidewire Software (Nasdaq: GWRE) and Orexigen ...
-
August 14, 2012
Arena Pharmaceuticals Inc. (ARNA) suffered a loss (excluding special items) of 12 cents per share in the second ...
-
July 23, 2012
After a bad morning, the Nasdaq has decreased 1.9%, the S&P 500 has slipped 1.3% and the Dow is down 1.1%. The ...
-
July 23, 2012
It's been a bad day for the market after the morning's trading. The Nasdaq is down 1.9%; the S&P 500 has fallen ...
-
July 18, 2012
Following a dry spell of thirteen years, the US Food and Drug Administration (FDA) approved two obesity drugs in the ...
-
July 18, 2012
The morning has been good for the market. The Nasdaq has risen 1.2%; the S&P 500 is up 0.6%; and the Dow has moved ...
